Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
Public ClinicalTrials.gov record NCT07008469. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Study identification
- NCT ID
- NCT07008469
- Recruitment status
- Enrolling by invitation
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Avidity Biosciences, Inc.
- Industry
- Enrollment
- 230 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 24, 2025
- Primary completion
- Jul 31, 2030
- Completion
- Sep 30, 2030
- Last update posted
- Apr 22, 2026
2025 – 2030
United States locations
- U.S. sites
- 17
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Los Angeles (UCLA) | Los Angeles | California | 90095 | — |
| Stanford University | Stanford | California | 94305 | — |
| University of Colorado | Denver | Colorado | 80045 | — |
| University of Florida | Gainesville | Florida | 32608 | — |
| University Research Center of South Florida | Tampa | Florida | 33612 | — |
| Indiana University (IU) | Indianapolis | Indiana | 46202 | — |
| Kansas University Medical Center | Kansas City | Kansas | 66205 | — |
| Kennedy Krieger Institute | Baltimore | Maryland | 21205 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Duke University Medical Center | Durham | North Carolina | 27708 | — |
| Wake Forest | Winston-Salem | North Carolina | 27157 | — |
| Ohio State University | Columbus | Ohio | 43221 | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | — |
| Houston Methodist Neurological Institute | Houston | Texas | 77030 | — |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | — |
| University of Washington | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07008469, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 22, 2026 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07008469 live on ClinicalTrials.gov.